Guidant Looking Beyond Boston Scientific's Paclitaxel Stent Dispute
This article was originally published in The Gray Sheet
Executive Summary
Cook's ability to establish Guidant as a "distributor" rather than a licensee of its paclitaxel application technology should result in a favorable outcome in the drug-coated stent dispute brought by Boston Scientific, Guidant claims.
You may also be interested in...
Drug-Coated Stents May Get ICD-9 Code In Time For Cypher Approval In 2003
Drug-eluting coronary stents are likely to receive a unique ICD-9-CM code in time for the first FDA approval of the devices, expected by Johnson & Johnson/Cordis in 2003
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.